Cargando…

Hyperprogression under immunotherapy: a new form of immunotherapy response?—a narrative literature review

OBJECTIVE: Update the last known review, and summarize the definitions, diagnostic criteria, reported risk factors, possible mechanisms and potential biomarkers of hyperprogressive disease (HPD) under immunotherapy. BACKGROUND: Immunotherapy is a relatively new systemic therapy adding a new method o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Miaozhen, Vanneste, Ben G. L., Yu, Qiwen, Chen, Zebin, Peng, Jiayu, Cai, Xiuyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350090/ https://www.ncbi.nlm.nih.gov/pubmed/34430364 http://dx.doi.org/10.21037/tlcr-21-575

Ejemplares similares

Hyperprogression under Immunotherapy
por: Frelaut, Maxime, et al.
Publicado: (2019)

Hyperprogression: A novel response pattern under immunotherapy
por: Han, Xue‐jiao, et al.
Publicado: (2020)

Hyperprogression after immunotherapy
por: Abbas, Waseem, et al.
Publicado: (2019)

Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench
por: Subbiah, Vivek, et al.
Publicado: (2022)

Is hyperprogressive disease a specific phenomenom of immunotherapy?
por: Brambilla, Marta, et al.
Publicado: (2020)

Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
por: Adashek, Jacob J., et al.
Publicado: (2020)

Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy
por: Wei, Zhanqi, et al.
Publicado: (2022)

Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics
por: Singla, Rishu, et al.
Publicado: (2021)

Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
por: Ji, Zhi, et al.
Publicado: (2019)

Hyperprogression of Liver Metastasis With Neoadjuvant Immunotherapy for Soft Tissue Sarcoma
por: Chan, Abigail S, et al.
Publicado: (2020)

Hyperprogression: A Unique Phenomenon of Progression of Existing Tumor Secondary to Immunotherapy
por: Mandal, Shobha, et al.
Publicado: (2021)

Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer
por: Xiong, Donghai, et al.
Publicado: (2018)

Hyperprogressive Disease After Immunotherapy: A Case Report of Pulmonary Enteric Adenocarcinoma
por: Hu, Chun-Hong, et al.
Publicado: (2022)

Exploration of the immunogenetic landscape of hyperprogressive disease after combined immunotherapy in cancer patients
por: Gong, Caifeng, et al.
Publicado: (2023)

Hyperprogression After Immunotherapy for Primary Small Cell Neuroendocrine Carcinoma of the Ureter: A Case Report
por: Qing, Defeng, et al.
Publicado: (2021)

Iodine-125 radioactive particles antagonize hyperprogressive disease following immunotherapy: A case report
por: Yang, Ning, et al.
Publicado: (2020)

Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer
por: Li, Yanping, et al.
Publicado: (2023)

Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report
por: Fricke, Jeremy, et al.
Publicado: (2020)

Narrative review of immunotherapy in thymic malignancies
por: Benitez, Jose Carlos, et al.
Publicado: (2021)

Immunotherapy as sensitizer for local radiotherapy
por: Vanneste, Ben G.L., et al.
Publicado: (2020)

Hyperprogression Under Immune Checkpoint-Based Immunotherapy—Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model
por: Kocikowski, Mikolaj, et al.
Publicado: (2020)

Non-gestational choriocarcinoma with hyperprogression on pembrolizumab: A case report and review of the literature
por: Kazemi, Nazanin Yeganeh, et al.
Publicado: (2022)

Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics
por: Refae, Sadal, et al.
Publicado: (2020)

The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy
por: Kim, Seo Ree, et al.
Publicado: (2021)

Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report
por: Varnier, Romain, et al.
Publicado: (2021)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Hyperprogressive Disease: Main Features and Key Controversies
por: Arasanz, Hugo, et al.
Publicado: (2021)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
por: Zang, Hongjing, et al.
Publicado: (2020)

Narrative review of immunotherapy and radiation therapy in elderly patients
por: Chau, Brittney, et al.
Publicado: (2021)

Narrative Review of Immunotherapy in Gastroentero-Pancreatic Neuroendocrine Neoplasms
por: Kaur, Jasmeet, et al.
Publicado: (2023)

Allergenic Characterization of New Mutant Forms of Pru p 3 as New Immunotherapy Vaccines
por: Gómez-Casado, C., et al.
Publicado: (2013)

Therapeutic challenge for immunotherapy targeting cold colorectal cancer: A narrative review
por: Ma, Shi-Xun, et al.
Publicado: (2023)

An overview of the published and running randomized phase 3 clinical results of radiotherapy in combination with immunotherapy
por: Vanneste, Ben G. L., et al.
Publicado: (2021)

Author Correction: Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics
por: Refae, Sadal, et al.
Publicado: (2020)

Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC
por: Rocha, Pedro, et al.
Publicado: (2020)

IFN-γ and CD38 in Hyperprogressive Cancer Development
por: Angelicola, Stefania, et al.
Publicado: (2021)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
por: Shen, Pan, et al.
Publicado: (2021)

Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease
por: Yildirim, Hasan Cagri, et al.
Publicado: (2022)

Immunotherapy and radiation for high-grade glioma: a narrative review
por: Fakhoury, Kareem R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_succ0pcu3o8icddnglj5153ai0